Anido says the company is on track to report results from CONNECT-FX, its clinical study of CBD in children and adolescents with Fragile X Syndrome in the second half of 2019. It has completed enrollment in its Phase 2 BELIEVE 1 of ZYN002 to treat epileptic encephalopathy, with top-line results will be reported in the third quarter of 2019.
View full ZYNE profile View Profile
January 31 2019
December 19 2018
October 18 2018